Hydroxycinnamic Acid Bioavailability via Flavonoid Sulfation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The bioavailability of hydroxycinnamic acids is limited in humans due to first-pass metabolism, primarily by Phase II enzymes such as sulfotransferases, which convert these compounds into sulfate conjugates, reducing their antioxidant capacity and efficacy.
Innovation Solution
Co-administering glycoside conjugates of flavonoids with hydroxycinnamic acids inhibits sulfation, thereby increasing the bioavailability and efficacy of hydroxycinnamic acids by reducing their conversion into sulfate conjugates, particularly in the human intestine and liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxycinnamic acids are consumed in the diet, then antioxidant capacity is provided, but first-pass metabolism by sulfotransferases converts them into sulfate conjugates, reducing their bioavailability and efficacy
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating hydroxycinnamic acids with sulfotransferase enzymes under controlled conditions to achieve partial sulfation before administration. This pre-sulfation reduces the burden on endogenous sulfotransferases during first-pass metabolism, thereby preserving more unconjugated hydroxycinnamic acids for systemic absorption and reducing the formation of inactive sulfate conjugates in the body
Solution Approach 2:
The patent employs parameter changes by modifying the degree of sulfation through controlled enzymatic treatment. By adjusting parameters such as enzyme concentration, incubation time, temperature, and substrate-to-enzyme ratio, the patent achieves optimal partial sulfation that balances stability during digestion with sufficient unconjugated form available for absorption, thus improving overall bioavailability
2Quantity of substance
If Phase II enzymes sulfate hydroxycinnamic acids, then sulfate conjugates are formed for excretion, but the free acids that provide antioxidant capacity are reduced in concentration
Solution Approach 1:
The patent applies preliminary action by performing controlled sulfation treatment on hydroxycinnamic acids before they enter the human body. This pre-treatment establishes a baseline level of sulfation that prevents excessive conversion during first-pass metabolism, thereby maintaining higher concentrations of free, active hydroxycinnamic acids in circulation
Solution Approach 2:
The patent converts the harmful effect of sulfation (which reduces bioavailability) into a beneficial process by using controlled enzymatic treatment to achieve optimal partial sulfation. This controlled conversion creates a protective effect that actually enhances the stability and bioavailability of hydroxycinnamic acids, turning the normally detrimental sulfation process into a beneficial pre-treatment step
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibition of sulfation by flavonoids and their conjugates leads to higher concentrations of unconjugated hydroxycinnamic acids in circulation, enhancing their antioxidant capacity and bioefficacy, effectively addressing the limitations of their bioavailability.
Implementation Method 1
Inhibitory effects of flavonoids and their conjugates on the sulfation of five major dietary hydroxycinnamic acids
Data Source
Figure 1A~1B
AI summary
The present invention generally relates to the field of nutrition, health and wellness. For example, the present invention relates to hydroxycinnamic acids and their health benefits. The present invention discloses compositions that allow increasing the bioavailability and/or bioefficacy of hydroxycinnamic acids. According to the invention, this can be achieved by co-administering at least one glycoside conjugate of a flavonoid with hydroxycinnamic acids.